Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Anexo makes Bringloe's CFO appointment permanent

(Sharecast News) - Credit hire and legal services provider Anexo Group has tapped Mark Bringloe to take over as chief financial officer. Anexo Group said Bringloe will take over as CFO, with immediate effect, after acting as interim CFO since August 2023.

Bringloe previously served as the AIM-listed group's CFO from the time of its admission to AIM in 2018 to July 2022.

Chairman Alan Sellers said: "Since Mark's return to the board he has continued to demonstrate his extensive knowledge of the group's operations, its business and its shareholder relationships and we are delighted to confirm Mark as CFO."

As of 1105 BST, Anexo shares were untraded at 65.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

Goldman Sachs downgrades SSP to 'sell', prefers WH Smith
(Sharecast News) - Goldman Sachs downgraded SSP on Monday to 'sell' from 'neutral' "on a relative basis" as it took a look at European travel concessions.
UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.